Dostinex contains the active ingredient cabergoline, a derivative of ergot. Cabergoline inhibits the secretion of the hormone prolactin at the pituitary level. Prolactin activates milk production in the mammary glands. Too high blood cell prolactin causes fertility disorders such as lack of menstruation or less abundant menstruation, lack of ovulation, and unwanted milky secretion (lactation). Dostinex is administered:
- to interrupt the physiological lactate secretion immediately after the birth, if for the patient it is contraindicated to breastfeed for medical reasons;
- to stop the milk secretion already in place, if indicated for medical reasons;
- to male and female patients with a high rate of prolactin, who have associated fertility disorders and undesirable milky secretion. A high rate of prolactin can be caused by a tumor of the pituitary gland.
Dostinex should only be used with a prescription.
Is it safe?
If you take more Dostinex tablets than you should: in case of overdose, tell a doctor immediately.
Absorption: After oral administration, cabergoline passes into the blood flow from the gastrointestinal tract and reaches its maximal concentration in blood plasma after 0.5 to 4 hours. Food does not seem to affect the absorption of cabergoline.
Distribution: In vitro studies have shown plasma protein binding of cabergoline to be 41 to 42% for concentrations ranging from 0.1 to 10 ng / mL.
Metabolism: In the urine, the main metabolite detected is 6-allyl-8β-carboxy-ergoline, which represents 4 to 6% of the dose. Three other metabolites have been identified in the urine; they represent globally less than 3% of the administered dose. In vitro, the inhibitory activity of prolactin secretion of metabolites is much lower than that of cabergoline.
Elimination: The elimination half-life of cabergoline is rather extended (63 to 68 hours in healthy volunteers and 79 to 115 hours in individuals with hyperprolactinemia, according to official data reflecting cabergoline pharmacokinetics).
Based on the elimination half-life, steady state should be reached after 4 weeks, the data backed up by average maximal plasma concentrations observed after a single dose of 0.5 mg cabergoline (37 mg / kg). ± 8 μg / ml) and after a repeated dose treatment of 4 weeks (101 ± 43 μg / ml).
Ten days after dosing, approximately 18% and 72% of the dose is excreted in urine and feces, respectively. In urine, cabergoline in unchanged form represents 2 to 3% of the dose.
Renal insufficiency / Hepatic insufficiency: In renal failure, it appears that excretion changes are minor. In patients with severe hepatic impairment, a decrease in the metabolism of the molecule is observed, leading to an increase in plasma concentrations of cabergoline and its derivatives.
Dostinex tablets should be taken with meals.
Dismissal immediately after birth
Dostinex should be taken in the first 24 hours after delivery. The recommended dose is 1 mg = 2 tablets. The 2 tablets should be taken at once.
Lactation with lactation already in place
The dose is ½ tablet (0.25 mg) of Dostinex every 12 hours for two consecutive days; altogether you should take 4 times ½ tablet.
In disorders with high rates of prolactin in the blood
Dostinex is given once or twice a week. Your doctor will prescribe the lowest dose at the start of treatment. Depending on the need, it will gradually increase the dose until there is a normalization of the prolactin rate in the blood and the regression of the disorders related to it.
The use of Dostinex in children, adolescents and the elderly has not been studied.
Do not change the prescribed dosage on your own initiative. If you think that the action of the medicine is too weak or too strong, talk to your doctor or pharmacist.
What does Dostinex contain?
1 tablet contains:
Active ingredient: 0.5 mg of cabergoline.
Auxiliary substances: lactose and leucine.
Where can Dostinex be obtained?
What packages are available?
Packs of 2 and 8 tablets.
In the pharmacy, upon presentation of the medical prescription.
Is there generic Dostinex available?
Generic Dostinex is available under the non-proprietary name of its active substance, Cabergoline, in the majority of online drugstores and selected city pharmacies.
The use of cabergoline is contraindicated in the following cases:
- Known hypersensitivity to cabergoline or ergot alkaloids;
- In case of uncontrolled hypertension;
- History of pulmonary, pericardial and / or retroperitoneal fibrotic disorders;
- In case of pre-existing cardiac valve disorders;